AN2 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-66.03	-64.73	-42.78	-28.06	-14.58
Depreciation & Amortization	0.03	0.05	0.08	0	0
Share-Based Compensation	8.73	8.41	4.39	0.97	0.04
Other Operating Activities	-2.02	2.98	3.03	0.09	8.2
Operating Cash Flow	-59.29	-53.29	-33.46	-20.48	-5.36
Change in Investments	-27.88	-43.28	-21.77	-50.02	0
Investing Cash Flow	-27.88	-43.28	-21.77	-50.02	0
Share Issuance / Repurchase	85.14	84.99	70.36	0.01	0.06
Other Financing Activities	-	-	-	78.52	3.77
Financing Cash Flow	85.14	84.99	70.36	78.54	3.84
Net Cash Flow	-2.02	-11.57	15.12	8.03	-1.53
Free Cash Flow	-59.29	-53.29	-33.46	-20.48	-5.36
Free Cash Flow Per Share	-1.99	-2.26	-2.18	-7.76	-2.09

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).